



Program

- 6.00 pm** **Welcome**
Michael Gnant (ABCSG President, Medical University Vienna, Austria)
- 6.05 pm** **CDK4/6 inhibitors - The big picture: what do we know so far?**
Mafalda Oliveira (Vall d'Hebron University Hospital, Barcelona, Spain)
- 6.20 pm** **Discussion**
Topic related Q&A
Michael Gnant and all speakers
- 6.25 pm** **Earlier than ever: defining the role of adjuvant CDK4/6 inhibition**
Part 1) CDK4/6 inhibitors as players in the adjuvant setting: scientific status quo
Florian Fitzal (ABCSG Expert, ATOMOS Klinik Währing, Vienna, Austria)
Part 2) From recent clinical trial data to clinical routine: what's out there already, what's coming?
Gabriel Rinnerthaler (ABCSG Expert, University Hospital Salzburg, Austria)
- 6.55 pm** **Discussion**
Topic related Q&A
Michael Gnant and all speakers
- 7.15 pm** **Breaking new grounds: what's next?**
Neoadjuvant setting: combination with oral SERDs – future outlook and impact on clinical routine
Christian Singer (ABCSG Expert, University Hospital Vienna, Austria)
- 7.35 pm** **Panel Discussion**
Implications to the clinical routine
What are the hurdles we need to overcome?
What is the paradigm shift in ABC?
Host: Michael Gnant
Panelists: All speakers and Marija Balic (ABCSG Expert, University Hospital Graz, Austria)
- 7.55 pm** **Wrap up & Closing**
Take home message
Michael Gnant

Registration via <https://www.abcsg.org/cdk46-2023/>